Adult Type 2 Diabetes
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as LY2963016 as compared to LANTUS® in adults with type 2 diabetes mellitus who are on 2 or more oral antihyperglycemic medications (OAMs).
The results of this study are not yet available.
Your participation in this trial could last up to 28 weeks and include 9 visits to the study center
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have type 2 diabetes mellitus (T2DM)and be capable and willing to perform self monitored blood glucose (SMBG), complete participant diaries as instructed, are receptive to diabetes education, and comply with required study treatment and study visits
Participant must not have taken basal plus mealtime insulin (basal bolus therapy) within the last year for greater than 4 continuous weeks
Participant must not have more than 1 episode of severe hypoglycemia within 6 months prior to screening
Participant must not have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening
Participant must not have known hypersensitivity or allergy to LANTUS®;
Participant must not have obvious signs or symptoms of liver disease, significant cardiac or gastrointestinal disease, history of kidney transplant or dialysis, or HIV
Participant must not have had a blood transfusion or severe blood loss within 3 months prior to screening
Participants must not have active cancer or personal history of cancer within the previous 5 years (with the exception of basal cell carcinoma or carcinoma in situ)
Participant must not be breastfeeding, pregnant or intend to become pregnant during the course of the study